Back to Top Skip to main content Skip to sub-navigation

COVID-19 Booster Shots are Now Available – What You Need to Know

Containers of the Pfizer COVID-19 vaccine. Each vial contains six doses for vaccination against the COVID-19 virus. Pfizer vaccines at Moody Air Force Base, Georgia, Sept. 9, 2021. Each Pfizer vial contains six doses for vaccination against the COVID-19 virus. (U.S. Air Force photo by Senior Airman Rebeckah Medeiros)

Recommended Content:

Coronavirus and the COVID-19 Vaccine | Coronavirus | COVID-19 Vaccine Efforts

Booster shots of Pfizer-BioNTech's COVID-19 vaccine are now available at military medical treatment facility and Department of Defense vaccination sites.

Those eligible for a Pfizer-BioNTech booster shot may also get them at commercial sites, such as civilian pharmacies or doctors' offices

All COVID-19 vaccines, including Pfizer-BioNTech's booster dose, may be given at the same time as the influenza vaccine (or other vaccines which may be due).

Fully vaccinated is still defined by the Centers for Disease Control and Prevention (CDC) as completing the 2-dose series for Pfizer-BioNTech or Moderna vaccines and the 1 dose for Johnson & Johnson/Janssen vaccine.

Booster Shots

Booster shots are now formally recommended for certain groups of people under an Emergency Use Authorization, according to recent announcements from the Food and Drug Administration (FDA) and the CDC.

For now, eligibility for a booster shot is limited to those who previously received a two-dose Pfizer-BioNTech COVID-19 vaccine for their initial vaccination.

At this time, booster shots are not recommended for those who initially received the Moderna two-dose vaccine and the Johnson & Johnson/Janssen single-dose vaccine or a mixed series of vaccines. However, those two populations will likely be recommended to receive a booster shot, and a formal recommendation for that may be forthcoming later this year as additional data are reviewed, according to the CDC.

Eligibility to voluntarily receive a single Pfizer-BioNTech booster vaccine includes people who are:

  • 65 years and older and residents in long-term care facilities
  • 18 and older in long-term care settings
  • 50-64 with underlying medical conditions
  • 18-49 with underlying medical conditions based on their individual benefits and risks
  • 18-64 who are at increased risk of COVID-19 exposure and transmission because of occupational or institutional settings such as teachers, frontline health care workers and essential workers, and those incarcerated, based on their individual benefits and risks.

To become eligible for a booster shot, there is a there is a six-month waiting period after the completion of the second dose of the Pfizer-BioNTech 2-dose vaccine.

Booster doses are not currently part of the DOD or federal worker mandates for COVID-19 vaccine requirements.

Proof of an underlying condition or an occupational risk is not required to receive a booster dose at an MTF or DOD vaccination site, and self-reporting of a condition eligible for a booster shot is allowed at any site where vaccines are available.

Comirnaty

The Pfizer-BioNTech COVID-19 vaccine is also known as the "Pfizer-BioNTech Comirnaty vaccine." The initial Pfizer-BioNTech vaccine was authorized for use under an FDA Emergency Use Authorization earlier this year, and the same vaccine assumed the new name, Pfizer-BioNTech Comirnaty, when it was fully approved by the FDA on Sept. 23. The two vaccines may be used interchangeably.

The COVID-19 shot being administered
Air Force Maj. Carla Cox, 59th Medical Wing commander’s executive officer, provides a COVID-19 vaccine to a San Antonio Military Health System beneficiary at Wilford Hall Ambulatory Surgical Center, Joint Base San Antonio-Lackland, Texas. (U.S. Air Force photo by Staff Sgt. Amanda Stanford)

The Comirnaty name (pronounced koe-mir' na tee) was developed from taking the Co from COVID-19, followed by the mRNA in the middle and ending with the 'ty' as a nod to immunity and community.

Third Shot vs. Booster

There is an important distinction between "booster shots" and "an additional dose."

A booster shot of the Pfizer-BioNTech COVID-19 vaccine is recommended for certain individuals at least six months after the second dose of the two dose Pfizer-BioNTech series. A booster shot aims to increase, or "boost", waning immunity observed over time, especially in those 65 years and older and residents of long-term care facilities. A familiar analogy of a booster shot may be the tetanus booster that is recommended every 10 years.

The option for an "additional dose" of mRNA vaccine (Pfizer-BioNTech or Moderna) was recommended in August for a comparatively smaller group of people who have compromised immune systems. This, unlike the booster dose, is because the primary 2-dose series of Pfizer-BioNTech or Moderna may not have resulted in a good enough antibody response; therefore an additional dose is recommended. The timing of an "additional dose" is at least 28 days after the second dose of an mRNA vaccine.

What about Moderna or Janssen Booster Doses?

Health officials may soon make a decision about whether to expand the recommendation for a booster beyond just those who received the Pfizer-BioNTech vaccine.

Moderna has already submitted data to the FDA for booster authorization. "A decision is expected soon," National Institutes of Health Director Francis Collins said Sept. 28. Earlier in September, J&J/Janssen submitted new data in support of a booster for its vaccine.

It's Time to Get Vaccinated

Both FDA and CDC noted that the populations most vulnerable to the SARS-CoV-2 coronavirus that causes COVID-19 continue to be those who are unvaccinated, and the nation's priority should remain getting everyone vaccinated with their primary series.

The approved and authorized COVID-19 vaccines continue to be effective in reducing severe, cases, hospitalizations, and deaths, even against the dominant Delta variant.

Most COVID-19 severe cases, hospitalizations, and deaths occur among the unvaccinated, around 99% of the time.

Hospitalizations rates are 10 to 22 times higher among unvaccinated adults compared to vaccinated adults, according to the CDC.

The CDC's Advisory Committee on Immunization Practices and the FDA Vaccines and Related Biologicals Advisory Committee will continue to follow the scientific data, and evidence will inform booster shot recommendations beyond the current ones.

Experts are looking at all available data to understand how well current vaccines are working for different populations - including looking at new variants Delta and Mu - to see how they affect vaccines' effectiveness.

While the COVID-19 vaccines currently available work to prevent severe illness, hospitalization, and deaths, public health experts are starting to see reduced protection, especially among certain populations, against mild to moderate disease.

"FDA and CDC have determined these booster shots can begin, based on the latest data and evidence, after a thorough, independent and transparent process of evaluating safety and effectiveness," the White House said in a Sept. 24 statement.

You also may be interested in...

How DHA monitors the spread of health outbreaks

Article
3/13/2020
The Armed Forces Health Surveillance Branch (AFHSB) is the central epidemiologic resource for the U.S. Armed Forces, conducting medical surveillance to protect those who serve our nation in uniform and allies who are critical to our national security interests. AFHSB provides timely, relevant, actionable and comprehensive health surveillance information to promote, maintain, and enhance the health of military and military-associated populations. (U.S. Air Force photo by Tech. Sgt. Nathan Lipscomb)

The Defense Health Agency works as a combat support agency to the military services and Military Health System

Recommended Content:

Combat Support | Public Health | Coronavirus | Coronavirus

DoD issues flexible instructions on response to Coronavirus

Article
3/13/2020
This illustration, created at the Centers for Disease Control and Prevention (CDC), reveals ultrastructural morphology exhibited by coronaviruses. The illness caused by this virus has been named coronavirus disease 2019 (COVID-19). (CDC Illustration)

The memo covers aspects from before the outbreak through all levels of infection

Recommended Content:

Combat Support | Public Health | Coronavirus | Coronavirus

Terry M. Rauch, Ph.D., M.P.H., M.B.A. Acting Deputy Assistant Secretary of Defense Force Health Protection and Readiness Regarding U.S. Biodefense and Response to the Novel Coronavirus Outbreak [Testified] Before the House Committee on Oversight and Reform

Congressional Testimony
3/11/2020

Recommended Content:

Coronavirus and the COVID-19 Vaccine | Coronavirus and the COVID-19 Vaccine | Coronavirus

COVID-19: Know what the terms mean

Article
3/10/2020
Image of a soldier taking the temperature of another soldier. Click to open a larger version of the image.

Learning the language can help you stay safe

Recommended Content:

Coronavirus | Public Health | Combat Support | Coronavirus

Coronavirus: What you need to know

Article
3/6/2020
A Guardsmen with the 341st Military Intelligence Battalion conducts translation work on a safety message regarding the best practices for avoiding the novel coronavirus for the Washington Department of Health on Feb. 9, 2020 at the Information Operations Readiness Center, Joint Base Lewis-McChord, Wash. (Courtesy Photo)

Although news stories and images contain many reports of people wearing surgical masks to ward off the virus, that's not recommended

Recommended Content:

Global Health Engagement | Public Health | Coronavirus | Coronavirus

DoD makes plans to combat Coronavirus

Article
3/4/2020
Defense Secretary Dr. Mark T. Esper and Army Gen. Mark A. Milley, chairman of the Joint Chiefs of Staff, speak to reporters at the Pentagon, March 2, 2020. (DoD photo Lisa Ferdinando)

The number one priority remains to protect our forces and their families

Recommended Content:

Coronavirus | Public Health | Combat Support | Coronavirus

MHS Prepared to Support Interagency Coronavirus Response

Article
2/6/2020
Airmen assist one another in donning their personal protective equipment, while on-board an Air Force C-17 Globemaster III during transportation isolation system training at Joint Base Charleston, South Carolina. Engineered and implemented after the Ebola virus outbreak in 2014, the TIS is an enclosure the Department of Defense can use to safely transport patients with diseases like novel coronavirus. (U.S. Air Force photo by Senior Airman Cody R. Miller)

From R&D to force health protection, MHS protects DoD personnel and families

Recommended Content:

Global Health Engagement | Public Health | Coronavirus | Coronavirus

DOD Releases Guidance to Protect Forces from Novel Coronavirus

Article
1/31/2020
The novel coronavirus is a variant of other coronaviruses, such as this colorized transmission electron micrograph of Middle East respiratory syndrome (MERS) virus particles (blue) found near the periphery of an infected VERO E6 cell (yellow). Image captured and color-enhanced at the NIAID Integrated Research Facility in Fort Detrick, Maryland. (Photo by NIAID)

Basic infection controls offer best defense against illness

Recommended Content:

Global Health Engagement | Public Health | Coronavirus | Coronavirus

MHS GENESIS Patient Portal Fact Sheet

Fact Sheet
7/30/2019

This fact sheet describes the MHS GENESIS Patient Portal.

Recommended Content:

Coronavirus and the COVID-19 Vaccine | MHS GENESIS Toolkit
<< < ... 41 42 43 44 > >> 
Showing results 646 - 654 Page 44 of 44

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.